Chennai-based startup MrMed, a direct-to-patient platform for critical care and super-specialty medicines, has announced a new phase of accelerated growth, driven by expanded physical infrastructure, enhanced cold-chain capabilities, and a widening national footprint.
Recognising the importance of timely access to life-saving and temperature-sensitive medicines, MrMed has expanded its physical presence with the establishment of on-ground operations in Guwahati, alongside its existing presence in Chennai, Delhi and Bengaluru. This expansion is aimed at strengthening last-mile access and improving fulfilment timelines across regions.
As part of its infrastructure expansion, the company has also launched an offline cold-chain storage facility in Bengaluru, reinforcing the city’s role as a strategic hub for faster fulfilment and improved patient access across Karnataka and the wider South India region. Chennai continues to serve as MrMed’s central operations and pharmacy hub.
MrMed is further advancing plans to expand its physical infrastructure across additional cities in India, with a continued focus on strengthening last-mile delivery for critical and temperature-sensitive medicines.
Looking ahead, MrMed is expanding its role within the healthcare ecosystem by entering allied super-specialty healthcare services, including home-based cancer care offerings such as nurse-led infusions and pre- and post-chemotherapy support. These initiatives aim to reduce hospital visits and improve continuity of care for patients undergoing extended treatment cycles.
MrMed works with authorised distributors of leading global and Indian pharmaceutical companies, including Eli Lilly, Novo Nordisk, Cipla, Dr Reddy’s, and Mankind, ensuring compliant sourcing and reliable access to life-saving therapies for patients across the country.
